Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFasting on Wegovy is not prohibited, but most people find the question answers itself once they start treatment. Semaglutide already reduces appetite significantly, and many patients naturally eat less without planning to. That said, some people want to combine deliberate fasting with their treatment, and it is worth understanding what the evidence actually supports before you decide. These are prescription-only medicines, so any significant change to how you eat alongside them is a conversation to have with your prescriber first.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Before deciding whether to fast, it helps to understand what semaglutide is already doing. Wegovy works on GLP-1 receptors in the brain and gut, slowing gastric emptying and signalling fullness sooner than usual. In practice, most people find their natural eating window shrinks. Meals feel satisfying after smaller portions, and the urge to snack between them often fades. The how semaglutide works page covers this mechanism in more detail.
This matters because many people arrive at something resembling intermittent fasting without intending to. They skip breakfast because they are simply not hungry, or find they are eating within a narrower window each day. If that happens naturally, it is generally fine. If you are weighing up whether intermittent fasting is something you can safely combine with Wegovy, the answer is more nuanced than a simple yes or no.
The NHS guidance for weight-management injections notes that treatment should sit alongside a reduced-calorie diet and increased physical activity, not replace meals entirely. Nutrient adequacy matters. Protein in particular supports the preservation of lean muscle mass during weight loss, and very low calorie intakes can make it harder to hit a sensible protein target. If you are curious about the broader context, what shapes the pace of weight loss on Wegovy is worth reading alongside this page.
Fasting is not dangerous for most healthy adults, but the combination with Wegovy introduces some specific considerations. Gastrointestinal side effects, including nausea, are most noticeable in the first few weeks of treatment and after each dose increase, as detailed in the NHS semaglutide medicines page. Eating very little during these windows can make nausea worse, not better. Small, bland meals spread through the day tend to settle the stomach more effectively than prolonged gaps.
Dizziness and low energy are also reported more often when food intake drops sharply. If you are moving through the titration schedule and also skipping meals, the two effects can compound. That is worth knowing, particularly if your job or daily routine requires concentration and physical stamina.
Dehydration is another factor. People who fast often drink more fluids to compensate, which is fine, but GLP-1 medicines already slow gut motility. Some people on Wegovy experience constipation, and a low calorie intake without enough fibre-rich food can add to that. Hydration and dietary fibre matter more, not less, when appetite is suppressed.
One more consideration: if you are thinking about whether you can fast while on Wegovy and find your weight is falling very quickly, that is not automatically a sign of success. Losing weight too fast on Wegovy carries its own risks, mainly loss of muscle rather than fat.
There is no randomised controlled trial that has specifically tested deliberate fasting protocols combined with semaglutide 2.4mg. What we have is evidence for semaglutide in combination with a structured reduced-calorie diet, which is the foundation of the licensed indication. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose alongside lifestyle intervention. Participants followed a calorie-deficit plan rather than fasting regimens.
The licensed indication for Wegovy specifically states use alongside a reduced-calorie diet and increased physical activity, as set out in NICE's appraisal of semaglutide for weight management (TA875). That framing points towards sustained, moderate calorie reduction rather than cyclical or extended fasts. Whether short-term fasting (such as a 16:8 eating window) interferes with or adds to outcomes is genuinely unknown from clinical trial data.
What is clear is that outcomes improve when protein intake is protected and muscle-supporting activity is maintained. Those two things are harder to achieve on aggressive fasting schedules, particularly early in treatment when the body is adapting. If you want a sense of the typical cost of private treatment before speaking to anyone, the Wegovy pricing page has the relevant context.
If you are already on Wegovy and wondering whether to add a fasting structure, pause and notice what is already happening. Are you hungry? Probably less than you expected. Are you eating less than before? Almost certainly. That natural reduction is part of how the treatment works, and forcing further restriction on top of it may not add much beyond increased side-effect risk.
If you have a specific reason to consider fasting, whether for religious observance, personal preference or a belief it will accelerate results, that conversation belongs with your prescriber. This is not because fasting is inherently incompatible with Wegovy, but because any significant departure from the eating pattern assumed in your prescription review is relevant clinical information. Your prescriber can help you plan around it safely, adjusting timing of the weekly injection relative to fasting windows if needed.
We understand that people come to this question from different places. Some are genuinely curious whether they can push harder; others are worried they are not doing enough. Either way, the medicine is already working on your appetite. Your job is mostly to eat well when you do eat, stay active, and keep your prescriber in the loop. If you would like a clinical view tailored to your situation, you are welcome to speak to our prescribers as part of your review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.